On the occasion of its Investor Day, Ipsen said it was aiming for average growth in total sales of at least 7% a year for the period 2023-27 at constant exchange rates, and an operating margin from.
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022: H1 2022 financial results